Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

DALLAS--(BUSINESS WIRE)--Jacobs selected by OCWUT to provide operations and maintenance services for the city’s wastewater facilities & solids management program....

TORONTO--(BUSINESS WIRE)--JD Power: Canadian Drivers Pay More at Dealerships, but Aftermarket Shops are Winning Their Trust...

ISTANBUL--(BUSINESS WIRE)--Türkiye’s leading mobility super app Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) today announced that its Board of Directors (the “Board”) has increased the authorization under the Company’s share repurchase program (the “Repurchase Program”) from $2.5 million to $5.0 million and extended the Repurchase Program through April 26, 2027.The expanded authorization reflects Marti’s continued commitment to disciplined capital allocation and provi...

SARASOTA, Fla.--(BUSINESS WIRE)--Belenos Biosciences, Inc. (“Belenos”), a clinical-stage biotechnology company developing long-acting bispecific antibodies for chronic inflammatory diseases, today announced positive interim results from its ongoing randomized, double-blind, placebo-controlled Phase 1b study of BEL512, an investigational long-acting bispecific antibody targeting thymic stromal lymphopoietin (“TSLP”) and interleukin-13 (“IL-13”), in patients with mild-moderate asthma. Phase 1b Tr...

TORONTO--(BUSINESS WIRE)--La valeur des récompenses et des avantages s'est imposée comme un facteur de différenciation essentiel parmi les titulaires de cartes de crédit au Canada, et représente désormais 53 % de la satisfaction globale, selon la JD Power 2026 Canada Credit Card Satisfaction StudySM , publiée aujourd'hui. Dans le même temps, de plus en plus de titulaires de cartes sont confrontés à des difficultés financières : 59 % d’entre eux sont considérés comme étant dans une situation fin...

TORONTO--(BUSINESS WIRE)--New Trolley research surveys 450 independent earners in 19 countries. Only 28% control when they're paid, and payout delays now drive platform churn....

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

COSTA MESA, Calif.--(BUSINESS WIRE)--Experian® has rolled out Experian Activate™, an AI-enabled decisioning engine powering the Experian Marketplace....